About The Study: Muvalaplin, an oral small molecule lipoprotein(a) inhibitor, reduced lipoprotein(a) measured using intact lipoprotein(a) and apolipoprotein(a)-based assays and was well tolerated. The effect of muvalaplin on cardiovascular events requires further investigation.
Corresponding Author: To contact the corresponding author, Stephen J. Nicholls, MBBS, PhD, email stephen.nicholls@monash.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.24017)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Heart Association’s Scientific Sessions 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.24017?guestAccessKey=f849b8a2-374c-4de8-87cc-7ee02b84e5f9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111824
JAMA